Trials / Completed
CompletedNCT03429075
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin + Placebo | Multiple dosing days psilocybin vs 6 weeks of daily placebo |
| DRUG | Psilocybin + Escitalopram | Multiple dosing days psilocybin vs 6 weeks of daily escitalopram |
Timeline
- Start date
- 2019-01-07
- Primary completion
- 2020-04-17
- Completion
- 2020-10-17
- First posted
- 2018-02-12
- Last updated
- 2024-10-24
- Results posted
- 2024-10-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03429075. Inclusion in this directory is not an endorsement.